Document Detail

Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants.
MedLine Citation:
PMID:  11779098     Owner:  NLM     Status:  MEDLINE    
In the present investigation, we studied the effect of recombinant human erythropoietin (r-HuEPO) on serum malondialdehyde (MDA) as an index of lipid peroxidation, related to iron-catalyzed free radical reaction and erythrocyte superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) activities in very-low-birth weight (VLBW) infants. Forty premature infants, at gestational ages were less than 33 weeks and birthweights were less than 1,500 g, were enrolled in the study. The study population was randomly divided into 2 groups. Twenty infants in Group 1 (treatment group) were given r-HuEPO, and 20 infants in Group 2 served as the control. r-HuEPO treatment (750 U/kg a week) was initiated on the 10th day of life and continued for 6 weeks. Preterm infants given erythrocyte transfusions during the study were excluded from the results. Serum ferritin and MDA levels, and erythrocyte superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) activities were analyzed at the end of the first week of life (at the beginning of the study). Subsequently, serum ferritin, and MDA levels were measured at the end of the 3rd and the 6th week. SOD, CAT, and GPX activities in the hemolysate were analyzed at the end of the 4th week. Six infants in the control group and 1 infant in the r-HuEPO group received transfusions through the end of the study, and these infants were excluded from the results. Significantly decreased serum ferritin concentrations were found in the r-HuEPO group compared to those in the control group both at the end of the 3rd and the 6th week (P < 0.05, and P < 0.01, respectively). In addition, serum MDA levels were also significantly reduced in Group 1 compared to control both at the end of the 3rd and the 6th week (P < 0.01 and P < 0.05, respectively). A good correlation was found between serum MDA and ferritin levels in Group 1. When the 2 groups were compared with respect to activities of SOD, CAT, and GPX at the end of the 4th week, no differences were observed. Our findings in this study show that administration of r-HuEPO significantly decreases lipid peroxidation, but does not affect erythrocyte antioxidant enzyme(s) activities in preterm infants. The mechanism responsible for the r-HuEPO-induced decrease in lipid peroxidation may concern inhibition to iron-catalyzed free radical reactions.
M Akisu; S Tuzun; S Arslanoglu; M Yalaz; N Kultursay
Related Documents :
4050728 - Does iron supplementation compromise zinc nutrition in healthy infants?
8025358 - Minerals and trace elements in infant nutrition.
20819898 - Iron supplements reduce the risk of iron deficiency anemia in marginally low birth weig...
18829838 - Sources of supplemental iron among breastfed infants during the first year of life.
12216828 - Evaluation of the natural refuge function for helicoverpa arnigera (lepidoptera: noctui...
7090188 - The postnatal development of monocular optokinetic nystagmus in infants.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Acta medica Okayama     Volume:  55     ISSN:  0386-300X     ISO Abbreviation:  Acta Med. Okayama     Publication Date:  2001 Dec 
Date Detail:
Created Date:  2002-01-07     Completed Date:  2002-06-06     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0417611     Medline TA:  Acta Med Okayama     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  357-62     Citation Subset:  IM    
Department of Pediatrics and Biochemistry, Ege University Medical School, Izmir, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aging / blood
Erythrocyte Transfusion
Erythrocytes / enzymology
Erythropoietin / therapeutic use*
Ferritins / blood
Infant, Newborn
Infant, Premature / growth & development,  metabolism*
Lipid Peroxides / metabolism*
Malondialdehyde / blood
Oxidoreductases / metabolism*
Recombinant Proteins / therapeutic use
Reference Values
Time Factors
Reg. No./Substance:
0/Lipid Peroxides; 0/Recombinant Proteins; 11096-26-7/Erythropoietin; 542-78-9/Malondialdehyde; 9007-73-2/Ferritins; EC 1.-/Oxidoreductases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of zinc deficiency/zinc supplementation on ammonia metabolism in patients with decompensated...
Next Document:  Retroperitoneal hematoma associated with femoral neuropathy: a complication under antiplatelets ther...